Analysts Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) Price Target at $19.59

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have been given a consensus recommendation of “Hold” by the twenty analysts that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $19.5909.

Several analysts have issued reports on the company. Wells Fargo & Company upped their target price on Intellia Therapeutics from $12.00 to $15.00 and gave the company an “equal weight” rating in a report on Tuesday, March 3rd. reissued a “buy” rating on shares of Intellia Therapeutics in a research report on Tuesday, March 3rd. Citizens Jmp boosted their price target on shares of Intellia Therapeutics from $21.00 to $28.00 and gave the company a “market outperform” rating in a research report on Tuesday, March 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Intellia Therapeutics in a report on Thursday, January 22nd. Finally, Leerink Partners lifted their target price on shares of Intellia Therapeutics from $27.00 to $29.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 3rd.

Insider Transactions at Intellia Therapeutics

In other news, CEO John M. Leonard sold 34,146 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $314,484.66. Following the completion of the sale, the chief executive officer owned 1,013,339 shares in the company, valued at $9,332,852.19. This trade represents a 3.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Birgit C. Schultes sold 8,508 shares of Intellia Therapeutics stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $78,358.68. Following the sale, the executive vice president directly owned 98,533 shares in the company, valued at approximately $907,488.93. The trade was a 7.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 53,051 shares of company stock worth $488,600 in the last 90 days. Insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rockefeller Capital Management L.P. lifted its stake in shares of Intellia Therapeutics by 1.7% in the 4th quarter. Rockefeller Capital Management L.P. now owns 140,218 shares of the company’s stock valued at $1,261,000 after purchasing an additional 2,277 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Intellia Therapeutics during the 4th quarter worth about $245,000. Invesco Ltd. raised its holdings in Intellia Therapeutics by 5.8% in the 4th quarter. Invesco Ltd. now owns 433,290 shares of the company’s stock valued at $3,895,000 after buying an additional 23,870 shares during the period. Axxcess Wealth Management LLC lifted its position in Intellia Therapeutics by 20.1% in the fourth quarter. Axxcess Wealth Management LLC now owns 21,399 shares of the company’s stock valued at $192,000 after buying an additional 3,583 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV acquired a new position in Intellia Therapeutics in the fourth quarter valued at about $90,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Performance

NTLA stock opened at $13.13 on Tuesday. The company has a market cap of $1.55 billion, a price-to-earnings ratio of -3.43 and a beta of 1.99. The firm has a 50-day moving average of $13.04 and a two-hundred day moving average of $13.37. Intellia Therapeutics has a 12 month low of $5.90 and a 12 month high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.99) by $0.16. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.The firm had revenue of $23.02 million during the quarter, compared to analysts’ expectations of $12.17 million. During the same quarter last year, the firm earned ($1.27) earnings per share. The business’s revenue for the quarter was up 78.4% on a year-over-year basis. As a group, equities analysts forecast that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.